CDC published a report October 1 on its very expensive, 43 month-long trial of anthrax vaccine, but inexplicably discussed only the first 7 months and only 65% of the subjects. No explanation was given for why only partial data were provided in this important paper.
Bloomberg may provide the reason; the selected data discussed in the paper do not explore the 229 serious adverse events that occurred. But the selected data will be used to support new recommendations for expanding vaccinations to civilians that CDC’s Advisory Committee will consider on October 22, 2008:
“After seven months, all the groups showed a comparable immune response, leading the researchers to say the three doses of the vaccine are “non-inferior.” The CDC’s Advisory Committee on Immunization Practice may make new recommendations on use of BioThrax that take the study’s findings into account, said Curtis Allen, a CDC spokesman.”
Yet other CDC officials told GAO in 2007 that 1-2% of vaccinees might have severe adverse events leading to disability or death.